Breakthroughs in Imaging Modalities for Prostate Cancer
March 3rd 2023Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.
Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL
October 20th 2022Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.
Novel Treatments Begin to Rival Transplant in AML and DLBCL
October 18th 2022Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.
Novel ADC and CAR T Approaches Broaden the DLBCL Treatment Landscape
October 17th 2022Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.
Continued Emergence of Targeted Therapies Reinforces Need for Frequent Genetic Testing in NSCLC
Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.